AM Biotechnologies

AM Biotechnologies develops synthetic DNA-based affinity reagents (X-Aptamers/Raptamers and thioaptamers) as alternatives to monoclonal antibodies for research, diagnostic, and therapeutic applications. The company's core technology addresses limitations of antibody production (batch variability, shelf life, production costs) by offering chemically synthesized, stable, and renewable affinity agents with nanomolar to picomolar binding affinity. The company has developed 42+ Raptamers for 60+ customers and maintains active research programs in therapeutic RNA synthesis, protein biomarker discovery, diagnostics, and applications targeting infectious diseases, cancer, genetic disorders, and drug addiction. AM Biotechnologies operates as a research-stage biotech company focused on platform technology development and commercialization rather than clinical drug development, with significant backing from government research funding agencies including NIH, NASA, DARPA, and the Bill & Melinda Gates Foundation. No clinical trials are reported.